Literature DB >> 11167696

Cholesterol supplementation objectively reduces photosensitivity in the Smith-Lemli-Opitz syndrome.

R M Azurdia1, A V Anstey, L E Rhodes.   

Abstract

Smith-Lemli-Opitz (SLO) affected children have multiple congenital physical and mental abnormalities; photosensitivity to ultraviolet A (UVA) has recently become a recognized feature. We present a patient with SLO and prominent photosensitivity in whom detailed phototesting has been performed at baseline and following 6 months of cholesterol supplementation. There was significant improvement in the symptoms of photosensitivity, confirmed objectively by phototesting and accompanied by partial correction of the biochemical abnormalities seen in SLO. This case report is the first to show that cholesterol supplementation in SLO can lead to an objective improvement in the associated photosensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167696     DOI: 10.1046/j.1365-2133.2001.03964.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

2.  7-Dehydrocholesterol enhances ultraviolet A-induced oxidative stress in keratinocytes: roles of NADPH oxidase, mitochondria, and lipid rafts.

Authors:  Antonio Valencia; Anpuchchelvi Rajadurai; A Bjorn Carle; Irene E Kochevar
Journal:  Free Radic Biol Med       Date:  2006-09-09       Impact factor: 7.376

3.  Statins for Smith-Lemli-Opitz syndrome.

Authors:  Rami A Ballout; Simona Bianconi; Alicia Livinski; Yi-Ping Fu; Alan T Remaley; Forbes D Porter
Journal:  Cochrane Database Syst Rev       Date:  2020

Review 4.  Smith-Lemli-Opitz syndrome.

Authors:  Andrea E DeBarber; Yasemen Eroglu; Louise S Merkens; Anuradha S Pappu; Robert D Steiner
Journal:  Expert Rev Mol Med       Date:  2011-07-22       Impact factor: 5.600

5.  Clinical utility gene card for: Smith-Lemli-Opitz Syndrome [SLOS].

Authors:  Martina Witsch-Baumgartner; Hilary Sawyer; Dorothea Haas
Journal:  Eur J Hum Genet       Date:  2013-01-16       Impact factor: 4.246

6.  Effects of cholesterol and simvastatin treatment in patients with Smith-Lemli-Opitz syndrome (SLOS).

Authors:  D Haas; S F Garbade; C Vohwinkel; N Muschol; F K Trefz; J M Penzien; J Zschocke; G F Hoffmann; P Burgard
Journal:  J Inherit Metab Dis       Date:  2007-05-11       Impact factor: 4.982

Review 7.  Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders.

Authors:  Melissa D Svoboda; Jill M Christie; Yasemen Eroglu; Kurt A Freeman; Robert D Steiner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-10-05       Impact factor: 3.908

8.  Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome.

Authors:  Simona E Bianconi; Joanna L Cross; Christopher A Wassif; Forbes D Porter
Journal:  Expert Opin Orphan Drugs       Date:  2015-03       Impact factor: 0.694

9.  Mutations in phospholipase C eta-1 (PLCH1) are associated with holoprosencephaly.

Authors:  Ichrak Drissi; Emily Fletcher; Ranad Shaheen; Michael Nahorski; Amal M Alhashem; Steve Lisgo; Alberto Fernández-Jaén; Katherine Schon; Kalthoum Tlili-Graiess; Sarah F Smithson; Susan Lindsay; Hayley J Sharpe; Fowzan S Alkuraya; Geoff Woods
Journal:  J Med Genet       Date:  2021-04-05       Impact factor: 6.318

10.  Photosensitivity in Smith-Lemli-Opitz syndrome: a flux balance analysis of altered metabolism.

Authors:  Bell Raj Eapen
Journal:  Bioinformation       Date:  2007-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.